Peptide Antibiotics Market to grow with a CAGR of 6.35%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Peptide Antibiotics Market.
According
to TechSci Research report, “Global Peptide Antibiotics Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Peptide Antibiotics
Market has valued at USD 4.90 billion in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 6.35% through 2028. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
Antibiotic stewardship programs play a crucial
role in shaping the demand for peptide antibiotics and antibiotics in general.
These programs are implemented in healthcare settings to promote responsible
and judicious use of antibiotics. While antibiotic stewardship programs are
primarily aimed at optimizing antibiotic use and curbing the rise of antibiotic
resistance, they can indirectly influence the demand for specific types of
antibiotics like peptide antibiotics. Antibiotic stewardship programs emphasize
the importance of selecting the most appropriate antibiotic for a given
infection. Peptide antibiotics, with their specific mechanisms of action and
limited spectrum of activity, can be valuable in achieving targeted therapy. When
stewardship programs recommend or require the use of specific antibiotics based
on microbial susceptibility testing, peptide antibiotics may be chosen if they
are effective against the identified pathogen. One key objective of antibiotic
stewardship is to reduce the unnecessary use of broad-spectrum antibiotics,
which can contribute to antibiotic resistance. Peptide antibiotics, often
having a narrower spectrum of activity, can be preferred in cases where a more
targeted approach is appropriate.
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on "Peptide Antibiotics Market”
Peptide
antibiotics are anti-infective and anti-tumor medications that contain
polypeptide chains. The two types of peptide antibiotics are those produced by
ribosomal synthesis and those produced by non-ribosomal synthesis. The benefits
of peptide antibiotics include their high specificity, high efficacy, and low
toxicity.
In
September 2021, to produce Daptomycin for injection to treat severe bacterial
infections, such as skin and soft tissue infections, bloodstream infections,
and endocarditis, AuroMedics Pharma LLC stated that it has gained permission
from the USFDA. Under the trade name Cubicin, daptomycin is a lipopeptide antibiotic
that is given intravenously. It displaces the bacterial cell membrane to
function. Gramicidin, which is often created in conjunction with other
antibiotics, shares a similar mechanism. With the caveat that oral use of this
medication may be harmful, it is an antibacterial agent for the topical
treatment of skin infections. This medication has a significant deal of
potential as a treatment for renal cell carcinoma, the most frequent kind of
kidney cancer in people, according to in vitro and in vivo research.
Patient adherence is a significant challenge
in the global peptide antibiotics market, as it is in healthcare more broadly.
Patient adherence refers to a patient's ability and willingness to follow
prescribed treatment plans, including taking medications as directed by
healthcare providers. Some peptide antibiotics may have complex dosing
regimens, requiring patients to take multiple doses at specific times or with
certain conditions (e.g., with or without food). These complexities can lead to
confusion and non-adherence. The frequency of administration can vary among
peptide antibiotics. Some may require multiple daily doses, while others are
administered less frequently. Frequent dosing can be burdensome for patients,
leading to missed doses. The duration of treatment with peptide antibiotics can
vary depending on the type and severity of the infection. Longer treatment
courses may increase the likelihood of non-adherence, as patients may
discontinue treatment prematurely.
Global Peptide Antibiotics Market segmentation is
based on
Type, Route of Administration, Distribution
Channel, Region and Company
Based on Type, Global Peptide Antibiotics Market is
segmented into Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized
Peptide Antibiotics.
Ribosomal synthesized peptide antibiotics are a class of antibiotics that are
produced by ribosomes, cellular structures responsible for protein synthesis,
within living organisms. These antibiotics are synthesized through ribosomal
machinery in response to specific genetic instructions encoded in the
organism's DNA. Ribosomal synthesized peptide antibiotics are naturally
occurring compounds that originate from living organisms such as bacteria,
fungi, and plants. They are a product of the organism's own metabolic
processes. These antibiotics exhibit structural diversity and can vary
significantly in size and complexity. They are composed of amino acids, the
building blocks of proteins, arranged in specific sequences. Ribosomal
synthesized peptide antibiotics are produced within the ribosomes of the
organism. Ribosomes read the genetic code in the organism's DNA and translate
it into a sequence of amino acids, forming the peptide antibiotic.
Based on Region, North America dominated the Global Peptide Antibiotics
Market. North America often hosts a significant number of clinical
trials, including those for new antibiotics. The availability of a diverse
patient population and experienced research centers makes it an attractive
location for conducting clinical research. The region has been actively
addressing antibiotic resistance concerns, leading to a focus on the
development of new antibiotics, including peptides, to combat drug-resistant
bacteria. The availability of venture capital, private equity, and funding
opportunities for pharmaceutical and biotechnology startups in North America
supports the research and development of novel antibiotics. The presence of
well-established pharmaceutical companies, biotech startups, and academic
research institutions in North America fosters competition and innovation in
the field of peptide antibiotics.
Asia-pacific region to fastest growth in
the Global Peptide Antibiotics Market. Many countries in the Asia-Pacific
region have been increasing their healthcare expenditure to improve healthcare
infrastructure and access to medical services. This includes investments in
research and development, which can boost the development and adoption of
peptide antibiotics. The Asia-Pacific region is home to a significant and
rapidly aging population. Older adults are more susceptible to infections,
driving the demand for antibiotics, including peptide antibiotics, to treat
age-related health issues and infections. Several emerging economies in Asia,
such as China and India, have been experiencing robust economic growth. This
growth has led to increased healthcare spending, improved healthcare access,
and greater demand for advanced medical treatments.
Some
of the major companies operating in the Global
Peptide Antibiotics Market include:
- Pfizer
Inc.
- Merck
& Co., Inc.
- AbbVie
Inc
- GSK
Group of Companies
- Sandoz
International GmbH
- Novartis
AG
- Xellia
Pharmaceuticals
- Novartis
AG
- Teva Pharmaceutical Industries Ltd.
- AuroMedics Pharma LLC
Download Free Sample Report
Customers can also request
10% free customization on this report
“Certain areas, particularly in
North America, are projected to exert significant demand for peptides. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Peptide
Antibiotics Market in the forecast period," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
Peptide
Antibiotics Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented by
Type (Non-Ribosomal Synthesized
Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), by Route of
Administration (Injectable, Oral, Topical), by Distribution Channel (Hospital
Pharmacy, Online Pharmacy & Retail Pharmacy), by region, and Competition evaluated
the future growth potential of Global Peptide Antibiotics Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Peptide Antibiotics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com